Literature DB >> 20453690

Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer.

Caroline O'Dowd1, Laura A McRae, Donald C McMillan, Alan Kirk, Robert Milroy.   

Abstract

BACKGROUND: Although only the minority of patients with non-small cell lung cancer (NSCLC) are suitable for surgical resection, it offers the best possibility of cure. The aim of this study was to examine the relationship between the clinicopathological status, the preoperative systemic inflammatory response, and survival in patients undergoing potentially curative resection for NSCLC.
METHODS: Data from 96 patients who underwent resection of NSCLC between 2000 and 2003 were collected retrospectively and that for 2004-2006 prospectively.
RESULTS: All patients had Eastern cooperative oncology group performance status 0 or 1. No patient had T4, unresectable nodal or metastatic disease, and all macroscopic tumors were removed, with subsequent negative surgical margins. The majority of patients were older than 60 years (71%), men (57%), underwent a lobectomy (65%), and had tumor, node, metastasis stage I disease (66%). Of the markers of the systemic inflammatory response, white cell count, C-reactive protein, and albumin, only an elevated C-reactive protein (>10 mg/L) was associated with cancer-specific survival. On multivariate analysis, only tumor, node, metastasis stage (hazard ratio 1.88, 95% confidence interval 1.34-2.63, p < 0.001) and preoperative C-reactive protein (hazard ratio 1.67, 95% confidence interval 1.01-2.83, p < 0.05) retained independent significance. Those patients with a preoperative C-reactive protein concentration >10 mg/L had a median survival of 26.2 months compared with 75.9 months in those patients with a C-reactive protein < or =10 mg/L (p < 0.05).
CONCLUSION: The results of this study indicate that the presence of a systemic inflammatory response predicts poor outcome in patients who have undergone potentially curative resection for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20453690     DOI: 10.1097/JTO.0b013e3181da78f9

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  21 in total

1.  Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.

Authors:  Jian Zhang; Shao-Hong Huang; Hui Li; Yun Li; Xiu-Ling Chen; Wei-Qing Zhang; Hui-Guo Chen; Li-Jia Gu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

2.  Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study.

Authors:  Xia Pu; Yuanqing Ye; Margaret R Spitz; Liang Wang; Jian Gu; Scott M Lippman; Michelle A T Hildebrandt; Waun Ki Hong; John D Minna; Jack A Roth; Ping Yang; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2012-09-13       Impact factor: 12.531

3.  The role of 18F-fluorodeoxyglucose uptake of bone marrow on PET/CT in predicting clinical outcomes in non-small cell lung cancer patients treated with chemoradiotherapy.

Authors:  Jeong Won Lee; Ki Hyun Seo; Eun-Seog Kim; Sang Mi Lee
Journal:  Eur Radiol       Date:  2016-09-02       Impact factor: 5.315

4.  Prognostic significance of the preoperative neutrophil-to-lymphocyte ratio for complete resection of thymoma.

Authors:  Masahiro Yanagiya; Jun-Ichi Nitadori; Kazuhiro Nagayama; Masaki Anraku; Masaaki Sato; Jun Nakajima
Journal:  Surg Today       Date:  2017-10-23       Impact factor: 2.549

Review 5.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 6.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

7.  Prediagnostic nonsteroidal anti-inflammatory drug use and lung cancer survival in the VITAL study.

Authors:  Theodore M Brasky; Christina S Baik; Christopher G Slatore; Mariela Alvarado; Emily White
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

8.  Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study.

Authors:  Adriana Villaseñor; Shirley W Flatt; Catherine Marinac; Loki Natarajan; John P Pierce; Ruth E Patterson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

9.  Platelet-to-lymphocyte ratio and C-reactive protein as markers for colorectal polyp histological type.

Authors:  Rui Chen; Liguang Wang; Qi Zhao; Zhen Li; Man Chen; Guodong Lian; Junyong Zhang
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.638

10.  Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Ya-Jun Li; Zhi-Ming Li; Yi Xia; Jia-Jia Huang; Hui-Qiang Huang; Zhong-Jun Xia; Tong-Yu Lin; Su Li; Xiu-Yu Cai; Zhi-Jun Wu-Xiao; Wen-Qi Jiang
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.